**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 84556

**Manuscript Type:** REVIEW

**Pathophysiological consequences and treatment strategy of obstructive jaundice**

Liu JJ *et al*. Obstructive jaundice

Jun-Jian Liu, Yi-Meng Sun, Yan Xu, Han-Wei Mei, Wu Guo, Zhong-Lian Li

**Jun-Jian Liu, Zhong-Lian Li,** Department of Hepatobiliary and Pancreatic Surgery, Tianjin Medical University Nankai Hospital, Tianjin 300102, China

**Yi-Meng Sun, Yan Xu, Wu Guo,** Graduate School, Tianjin Medical University, Tianjin 300070, China

**Han-Wei Mei,** Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China

**Author contributions:** Li ZL and Liu JJ wrote and edited the manuscript; Sun YM and Mei HW made the Figure of the manuscript; Xu Y and Guo W edited and formatted the manuscript; all authors have read and approved the final manuscript.

**Supported by** Tianjin Municipal Education Commission Scientific Research Program, China, No. 2022KJ271.

**Corresponding author: Zhong-Lian Li, MD, PhD, Doctor, Professor,** Department of Hepatobiliary and Pancreatic Surgery, Tianjin Medical University Nankai Hospital, No. 6 Changjiang Road, Tianjin 300102, China.nkyylzl@163.com

**Received:** March 20, 2023

**Revised:** April 29, 2023

**Accepted:** May 31, 2023

**Published online:** July 27, 2023

**Abstract**

Obstructive jaundice (OJ) is a common problem in daily clinical practice. However, completely understanding the pathophysiological changes in OJ remains a challenge for planning current and future management. The effects of OJ are widespread, affecting the biliary tree, hepatic cells, liver function, and causing systemic complications. The lack of bile in the intestine, destruction of the intestinal mucosal barrier, and increased absorption of endotoxins can lead to endotoxemia, production of proinflammatory cytokines, and induce systemic inflammatory response syndrome, ultimately leading to multiple organ dysfunction syndrome. Proper management of OJ includes adequate water supply and electrolyte replacement, nutritional support, preventive antibiotics, pain relief, and itching relief. The surgical treatment of OJ depends on the cause, location, and severity of the obstruction. Biliary drainage, surgery, and endoscopic intervention are potential treatment options depending on the patient's condition. In addition to modern medical treatments, Traditional Chinese medicine may offer therapeutic benefits for OJ. A comprehensive search was conducted on PubMed for relevant articles published up to August 1970. This review discusses in detail the pathophysiological changes associated with OJ and presents effective strategies for managing the condition.

**Key Words:** Jaundice; Obstructive; Pathophysiology;Treatment strategy; Traditional Chinese medicine

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Liu JJ, Sun YM, Xu Y, Mei HW, Guo W, Li ZL. Pathophysiological consequences and treatment strategy of obstructive jaundice. *World J Gastrointest Surg* 2023; 15(7): 1262-1276

**URL:** https://www.wjgnet.com/1948-9366/full/v15/i7/1262.htm

**DOI:** https://dx.doi.org/10.4240/wjgs.v15.i7.1262

**Core Tip:** Obstructive jaundice is a complex condition with systemic effects, and its management requires a multidisciplinary approach. Adequate supportive measures and identification of the cause, location, and severity of obstruction are crucial for effective treatment. Surgical and endoscopic interventions, as well as medical treatment, can be valuable options, depending on the patient's condition. Therefore, a thorough understanding of the pathophysiology and a comprehensive approach to management are necessary for better outcomes.

**INTRODUCTION**

Jaundice manifests as a yellowish pigmentation of the skin and sclera, which is caused by interrupted or impaired excretion of bilirubin and biliverdin. Obstructive jaundice (OJ), *i.e*., obstructed bile outflow, can be either intrahepatic or extrahepatic. Intrahepatic OJ can be subdivided into non-obstructive intrahepatic cholestasis and obstructive intrahepatic obstructive cholestasis. Non-obstructive intrahepatic cholestasis may result from viral hepatitis, drug-related cholestasis (*e.g*., caused by chlorpromazine, methandrostenolone, and birth control pills), primary biliary cirrhosis, or intrahepatic cholestasis during pregnancy[1]. In contrast, obstructive intrahepatic cholestasis occurs due to intrahepatic sediment-like stones, cancerous emboli, or parasitic infections (*e.g*., *Toxoplasma gondii* infection)[2-4]. Extrahepatic cholestasis can be caused by obstruction of the common bile duct by stones, strictures, inflammatory edema, biliary atresia, bile duct injury, tumors, pancreatic tuberculosis and roundworms[5-7]. The occurrence of jaundice is also related to genetic factors[8]. Common bile duct stones are undoubtedly the leading cause of extrahepatic biliary obstruction, and bile duct cancer, malignancies such as periampullary and pancreatic cancer, and benign strictures including chronic pancreatitis have become increasingly common[9-11].

OJ can result in various pathophysiological consequences, including local effects on the hepatic parenchyma, biliary tree, and systemic manifestations[12]. Consequently, patients with jaundice are at a high risk of developing liver dysfunction, renal failure, nutritional deficiencies, bleeding tendencies, compromised immunity, infections, and increased morbidity and mortality. A comprehensive understanding of the pathophysiology in patients with jaundice (Figure 1) is crucial to implementing optimal preventive measures and improving the outcomes[13]. Currently, surgical intervention remains the predominant approach for treating OJ[14]. However, pre-operative jaundice typically results in liver cell damage, liver dysfunction, biliary tract infections, skin itching, and pain, which requires comprehensive management (Figure 2). Traditional Chinese medicine (TCM) offers important complementary and alternative therapy approaches to relieve these symptoms[15]. Therefore, TCM can constitute an adjunctive treatment modality. This review provides a detailed analysis of the pathophysiological manifestations and various treatment strategies for bile stasis resulting from extrahepatic OJ. The article aims to offer a comprehensive understanding of this medical condition and the potential solutions available for managing it.

**Pathophysiological consequences**

***Effects on the biliary system***

Under physiological conditions, the pressure in the biliary tract ranges from 5 to 10 cmH2O. Any obstruction of bile transport and excretion results in increased pressure in the bile duct, and when the pressure exceeds 10-15 cmH2O, the liver no longer excretes bile[16].

Bile sludge facilitates the growth and proliferation of microorganisms in the bile, whereas under normal conditions, bile is sterile. The duodenal microflora ascends retrogradely along the bile duct. During biliary obstruction, the pressure in the bile duct above the obstruction increases, and the bile duct dilates, causing rupture of the small and capillary bile ducts, and bilirubin in the bile flows back into the blood. As the pressure in the biliary tree increases, its barrier function is compromised, leading to increased permeability and bile reflux into the hepatic sinusoids; consequently, this reflux into the blood leads to the entry of microorganisms and their degradation products in the body circulation system. Cholangitis occurs mainly during acute obstruction. Elevated biliary pressure pushes bacteria into the bile ducts, hepatic veins, and perihepatic lymphatics, which results in bacteremia[17,18]. Increased pressure in the bile ducts during acute cholangitis frequently renders the ducts more permeable to bacteria and toxins, leading to severe infection and sepsis[19]. In addition, bile reflux leads to inflammatory infiltration of polymorphonuclear neutrophilic leukocytes into the portal sinus and increases fibrin deposition.

***Effects on the structure of the liver***

Jorge *et al*[20] used experiments to observe that neutrogranular inflammatory cytocytosis in rat liver tissue with OJ showed liver contour changes, liver fibrosis, ductal hyperplasia, inflammatory portal vein infiltration, regenerated nodules, port-portal septum, and necrotic foci, with severe cases developing cirrhosis. Margaritis *et al*[21] found that in rats with jaundice through bile duct ligation (BDL), bilirubin values increased significantly, liver tissue bacterial cultures were positive, and endotoxin values collected from the portal vein and aorta were significantly higher than those in the controls. Liver biopsy revealed tubular cholestasis and portal vein changes, portal vein dilation, ductal hyperplasia, and neutrophil inflammation.

Ozozan *et al*[22] created an OJ model in rats by ligating the bile duct. In their experiments on liver cell damage, they observed large lipid particles were observed in liver tissue indicating oxidative damage to the liver, but increases in indium tin oxide particles, lipid particles, and normal mitochondria were observed after removal of the obstruction, reflecting the regenerative function of liver cell structure and suggesting that liver damage after obstruction may be reversible. The liver biopsy study of Vij *et al*[5] revealed that the primary pathologic characteristic of OJ caused by biliary atresia was the dilation of the portal vein bundle, showing edema fibrosis with biliary tract hyperplasia, typically involving fibroblasts and different inflammatory cells. Portal vein bundles may also show hematopoietic components, especially myelopoiesis. Luo *et al*[23] conducted a study using rat experiments to investigate the effects of OJ on the liver. They stained liver sections of rats with OJ with hematoxylin-eosin, revealing bile duct epithelial lesions including fuller epithelial cells in the bile duct, disordered cell morphology, thickening of the basement membrane, edema in the interstitium of the common bile duct, increased thickness of small bile ducts, and dilation of the bile duct. Additionally, irregular masses were observed around liver cells, and over time, the fibrous membrane thickened, leading to an increase in fiber spacing. Zhang *et al*[24] found that rats with BDL formed jaundice lesions, and compared with the controls, the treated rats showed hepatocyte apoptosis, endotoxemia, reduced plasma glutathione, and rapidly increased oxidized glutathione levels; further, the tight junctions of hepatocyte structures were destroyed, and oral administration of *Lactobacillus plantarum* helped restore the barrier function of liver activity.

***Effects on hepatic vasoconstriction and hemodynamics***

OJ damages the endothelial cells of the hepatic sinuses, rendering the liver more susceptible to ischemia-reperfusion, and reduces vasoconstrictor tension and lowers vasoreactivity. Reactive oxygen species (ROS) play a major role in the pathogenesis of jaundice as they reduce the bioavailability of nitric oxide, thereby impairing vasodilation and endothelial cell growth, causing oxidative damage which may lead to atherosclerosis[25,26], Color Doppler flow imaging is an ideal non-invasive method for monitoring hepatic artery and portal blood flow. If there is a more significant increase in hepatic arterial blood flow compared to the decrease in portal blood flow, it indicates a smoother postoperative recovery of liver function and a better prognosis[27].

The presence of portosystemic venous shunts in OJ exacerbates endotoxin entry into systemic circulation. Endotoxins are components of the cell walls of gram-negative bacteria, termed lipopolysaccharides (LPS)[28]. Small amounts of endotoxins are produced in the gut under normal conditions, and the liver is a central immunological organ that is particularly enriched in innate immune cells and constantly exposed to circulating nutrients and endotoxins derived from the gut microbiota[29]. Endotoxins may occur due to damage to Kupffer cells, which allows endotoxins to enter systemic circulation. During OJ, insufficient bile flow and other factors that predispose to portal endotoxin absorption and impaired reticuloendothelial function allow the development of systemic endotoxemia. Obstruction of the intestine after bile enters the intestine leads to abnormal proliferation of the normal flora, resulting in damage to the intestinal mucosal barrier of the intestinal mucosa, bacterial translocation, and ultimately, increased endotoxin absorption[30]. Endotoxins in the blood circulation cause organ damage by stimulating various cells such as monocytes, macrophages, granulocytes, and endothelial cells to produce cytokines such as tumor necrosis factor (TNF), platelet-activating factor, interleukin (IL), oxygen radicals, prostaglandins (PG), and procoagulants. This may explain why patients with OJ frequently experience complications such as infection, gastrointestinal bleeding, renal failure, wound nonunion, and even multi-organ failure after surgery[31,32].

***Effects on the kidney***

In 1990, a retrospective study revealed that 49% of patients with hepatoportal cholangiocarcinoma (HCCA)-associated OJ (130 cases) had developed acute renal failure[33]. The incidence of this complication ranges from 5% to 16%, and patient mortality rates were approximately 70%-80%[34,35].

OJ kidney injury (OJKI) is a form of kidney injury that occurs due to an obstruction of the bile ducts, which causes accumulation of bile acids (BAs) in the body. The kidneys are responsible for removing excess BAs from the body, and when the natural excretory route for BAs is blocked, the kidneys become the primary organ for excretion. BA accumulation in the body can lead to renal tubular epithelial injury, which can cause OJKI. In animal models of OJ, feeding hydrophilic nordemethyldeoxycholic acid in advance can inhibit renal tubular epithelial injury, indicating that toxic BAs excreted through the urine are a key trigger factor of OJKI[36]. This indicates that toxic BAs excreted through the urine are a key trigger factor of bile cast nephropathy, which causes renal tubular epithelial injury in mice with BDL[37]. In addition, OJKI may also be caused by gut-derived endotoxemia, which can affect various bodily functions, including the clotting system, hemodynamic balance, inflammation, and oxidative damage. For example, Houdijk *et al*[38] observed that renal blood flow in rats with BDL was significantly lower than in sham-operated rats, and limiting gut endotoxins prevented the decrease of renal blood flow.

In cases of OJKI, hemodynamic disturbances can occur as a result of liver dysfunction and kidney injury. The liver plays a key role in maintaining normal blood flow and pressure, and damage to the liver can lead to changes in systemic blood flow and pressure. Based on renal hypoperfusion, disturbances and changes in renal hemodynamics are the basic mechanisms underlying OJKI. Hypotension resulting from hemodynamic disturbance further aggravates the ischemic state of the kidney[39] which is highly sensitive to ischemia and prone to renal insufficiency[40]. The renin-angiotensin-aldosterone system (RAAS) is a key player in the progression of renal diseases. Inhibiting renin and aldosterone, which blocks the RAAS, is an effective way to prevent OJKI[41]. Naranjo *et al*[42] conducted a study on rats with OJKI and found that urinary prostaglandin E2 (PGE2) secretion increased in OJ rats. Rats with creatinine clearance lower than the average excreted less PGE2 into the urine. This indicates that PGE2 may play a protective role in the kidney and prevent the deterioration of renal functioning.

Oxidative stress (OS) is caused by an imbalance between the oxidation and antioxidation systems when the body is exposed to accumulation of numerous harmful factors, such as drugs, toxic metabolites, cholestasis, and alcohol metabolism products. In a prospective study on patients with OJ, the level of lipid peroxide in the blood was a predictor of OJKI and was closely related to age; further, renal impairment was more frequent in OJ patients than in healthy individuals[43]. The levels of cholesterol and malondialdehyde in the mitochondrial membrane of rats increased with the time of common bile duct obstruction and the degree of OJKI[44]. At the obstruction stage, the level of superoxide dismutase in rat kidneys decreased and was negatively correlated with renal apoptosis and endotoxin. This suggests that free oxygen radicals participate in the process of OJKI in rats.

***Effects on the gut and intestinal barrier***

Under normal physiological conditions, bile flows freely through the bile ducts, which helps remove bacteria and prevents their migration from the small intestine to the bile duct by the action of the sphincter of Oddi[45]. Bile also has anti-inflammatory functions. However, when the bile duct is obstructed, cholestasis occurs, and bacteria can multiply due to the absence of bile in the intestine and the accumulation of BAs in the systemic circulation. This, in turn, leads to OS injury of the intestinal mucosal epithelium, destruction of the intestinal tight junctions, and down-regulation of small intestinal tight junction protein expression[31]. Ultimately, these changes result in the destruction of the intestinal tissue structure and disintegration of the intestinal mucosal barrier function, which then allows for intestinal endotoxins and bacteria to enter systemic circulation.

***Effects on the immune system***

Bile affects the homing and distribution of T lymphocytes in intestine-associated lymphoid tissue. Thus, the absence of bile in the intestinal lumen leads to a decrease in the abundance of CD4+ and CD8+ T lymphocytes and mucosal cell adhesion molecule 1-expressing cells in the lamina propria[46]. Bile also affects the size and abundance of B lymphocytes in Peyer's patches, and the absence of bile in the intestinal lumen induces apoptosis of B lymphocytes in Peyer's patches. Bile contains immunoglobulin A, which enhances mucosal defenses or binds to bacteria and viruses. This suggests that bile is essential for maintaining local immune barrier functioning in the intestine[47].

Immune dysfunction leads to higher susceptibility to the translocation of intestinal bacteria, and immune dysfunction in patients with jaundice can also lead to a systemic inflammatory response[48]. Activated macrophages are highly sensitive to high concentrations of total BAs. Therefore, accumulation of hepatic and circulating total BAs may kill or severely damage activated macrophages (or Kupffer cells), thereby impairing hepatic and systemic immune functions and accelerating the development of sepsis in patients with OJ[49].

***Effects on the coagulation system***

It is widely accepted that patients with OJ are at a higher risk of developing thromboembolism. Research into procoagulant activity, specifically by measuring coagulation time, fibrin formation, and purified coagulation complexes, has revealed that the presence of neutrophil extracellular traps (NETs) in patients with OJ is significantly higher than in healthy individuals. This suggests that targeting NET values could be a promising approach to improving coagulation disorders in OJ patients[50]. Cakir *et al*[51] conducted a study that observed hypercoagulability in more than half of patients with OJ. The coagulation index was found to be associated with an increase in direct bilirubin concentration, but the hypercoagulability trend appeared to be independent of prothrombin time (PTT), possibly due to increased activity of fibrin polymers on platelet membranes.

Prentice *et al*[52] found that OJ may lead to acquired coagulation disorders, insufficient bile salt secretion leading to vitamin K malabsorption, insufficient coagulation factor synthesis after hepatocyte failure, inability to clear coagulation and fibrillin activation products, and disseminated intravascular coagulation. Deficiency in vitamin K due to reduced absorption can result in bleeding diathesis, even with normal laboratory indices, such as PTT and international normalized ratio (INR). Furthermore, reduced absorption of other fat-soluble vitamins, such as vitamin D, and lipids can lead to their deficiency, resulting in a reduction in calcium levels[53,54].

**The treatment of OJ: medication and surgery**

***Medical treatment***

OJ may lead to bilirubin accumulation in the bloodstream, and infection can occur when there is an obstruction in the bile ducts. In addition to jaundice, patients with OJ may experience symptoms including fever, abdominal pain, nausea and vomiting, dark urine, pale stools, pruritus, fatigue, lack of appetite, and nutritional deficiencies. These symptoms can be managed with medications and nutritional support, respectively. Of note, the symptoms of OJ may vary depending on the severity and underlying cause of the obstruction.

**Treatment of pain:** Depending on the degree and type of pain, several medication options are available for patients with abdominal pain. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for mild to moderate pain relief[55,56]. These include medications such as aspirin, ibuprofen, and naproxen. Acetaminophen (APAP) is a pain reliever and fever reducer that is used for mild to moderate pain relief. While NSAIDs can be effective for managing pain and inflammation, they come with potential risks. One of the main concerns is that they can cause upper gastrointestinal bleeding, congestive heart failure, and renal failure. Kidney damage is a particular risk, as NSAIDs can reduce renal blood flow and glomerular filtration rate, cause sodium and water retention, and lead to hyperkalemia and water poisoning. Patients with cirrhosis or asthma should avoid using NSAIDs altogether, and caution is necessary when administering them to patients taking anticoagulants prior to surgery. Adequate hydration and drug testing before using NSAIDs can help prevent or reduce the risk of acute kidney injury[57,58]. Opioids are strong pain relievers for moderate to severe pain relief. Examples of opioids include morphine, codeine, and hydrocodone[59].

**Antibiotics and anti-inflammatory treatment:** When OJ is complicated by an infection, it should be treated with appropriate antibiotics. Most infections are caused by gram-negative bacteria. The local microbial epidemiology should be considered in the selection of antimicrobial agents for initial empirical therapy. The appropriate anti-infective regimen is selected after assessing the severity of the patient's disease and the risk of infection with drug-resistant pathogens. Initial treatments include quinolones (ofloxacin, ciprofloxacin, *etc.*), beta-lactam antibiotics (penicillin, carbapenems, cephalosporins, cephalosporins, *etc.*), and nitroimidazole antibiotics[60,61]. Commonly used drugs include ampicillin-sulbactam, piperacillin-tazobactam, ticarcillin-clavulanic acid, cephalosporins plus metronidazole, imipenem-cilastatin, and ciprofloxacin plus metronidazole[62,63]. Blood cultures are usually taken from a patient before they receive antibiotics to diagnose the infection. However, it is essential to note that these cultures yield positive results in less than 40% of cases[64]. Hence, clinicians must rely on empiric therapy with the local antibiogram's knowledge to manage patients with biliary sepsis. Bile cultures are obtained and drug sensitivity tests are performed in patients after biliary drainage. This is done to identify the presence of infections and to determine the type of pathogenic bacteria and the antibiotic to which they are sensitive. Pseudomonas aeruginosa infections are commonly treated with a combination of antibiotics such as β-lactams, aminoglycosides, and polymyxins. On the other hand, when patients develop fungal infections, antifungal drugs such as fluconazole, metronidazole, and echinocandins are usually prescribed[65]. Corticosteroids are anti-inflammatory medications that reduce inflammation in the body and which can alleviate pain and fever. Patients with fever may also benefit from physical cooling or NSAIDs. While antibiotics are an essential part of treating infections, they are not always sufficient on their own. Drainage or a definitive surgical procedure may also be necessary to fully address the issue, as stated in reference[64].

**Antiemetic treatment:** Patients with nausea and vomiting can take certain medications such as ondansetron, metoclopramide, or promethazine to relieve the discomfort. Metoclopramide is an empirically established drug for patients with vomiting. Central antiemetics such as selective serotonin type 3 (5HT3) antagonists (ondansetron and granisetron) for patients with malignancies treated with chemoradiotherapy. Vomiting can also be treated with neurokinin 1 receptor antagonists (fosaprepitant and aripitant) and synthetic cannabinoids (nabilone). Patients with vomiting are frequently treated with hydration and electrolytes to replace lost fluids. Clinical studies have shown that anti-dopamine agents (haloperidol, levocarnitine, or olanzapine) are very effective in stopping emetics[66].

**Treatment of pruritus:** During cholestasis, compounds that are typically eliminated in bile build up in the tissues[67]. Although the exact nature of pruritogens (substances that cause itching) is unknown, it is believed that they accumulate in the plasma due to cholestasis. Ursodeoxycholic acid, chenodeoxycholic acid, cholic acid, cholestyramine[68], the antibiotic rifampin[69], and the selective serotonin reuptake inhibitor sertraline[70] can be prescribed to help reduce itching in OJ patients. Opioid antagonists[71] such as naloxone, naltrexone, and nalmefene can reduce itching in various cases. In addition, treatment with ondansetron can decrease pruritus effectively[72]. Peroxisome proliferator-activated receptor (PPAR) is a fatty acid-activated transcription factor of the nuclear hormone receptor superfamily. Bezafibrate, a PPAR agonist, can significantly reduce the levels of alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin in the blood. Fibroblast growth factor 19 agonists and their synthetic analog aldafermin (NGM282) markedly improve liver function[72]. Furthermore, skincare and cooling compresses can also reduce itchy symptoms. Phototherapy can alleviate itching in some cases. Thirteen patients with pruritus symptoms due to different cholestatic liver diseases were examined in a previous study, and ultraviolet B phototherapy was performed three times per week until the visual analog scale scores of perception of itching did not improve further or the patient's itching symptoms improved by 80%; 77% of the patients reported > 60% reduction in perceived pruritus[73].

**Nutritional support:** Various treatment options for patients with nutritional deficiencies are available. Depending on the specific deficiencies, nutritional supplements may be prescribed to help replace missing nutrients. For example, fat-soluble vitamins, electrolytes such as sodium, potassium, and magnesium as well as water, protein, and fats may be supplemented[74,75]. In severe cases where oral nutrition is not possible, parenteral nutrition may be administered intravenously to provide essential nutrients[76].

**Supplementation of pancreatic exocrine enzyme:** In some cases, pancreatic exocrine insufficiency may occur in the presence of malignant biliary obstruction such as due to pancreatic cancer. After surgical resection of pancreatic cancer, patients may develop pancreatic exocrine insufficiency. Digestive enzyme replacement therapy may be used to help improve the digestion and absorption of nutrients[77]. A retrospective population-based observational cohort study was conducted by Roberts *et al*[78], with 1614 subjects, i.e., 807 matched pairs. Propensity-matched analysis showed significantly higher median survival in patients receiving pancreatic enzyme replacement therapy.

***TCM treatment***

While there are modern medical treatments for this condition, TCM has shown promise as a complementary therapy approach for its management. In TCM, several herbal remedies are used to treat OJ, as listed below.

**Cholagogue herbs:** These herbs help improve the flow of bile and reduce the buildup of bile in the blood. Examples of cholagogue herbs include *Curcuma aromatica* (Yu Jin), *Curcuma zedoaria* (E Zhu), and *Lysimachia christinae* (Jin Qiancao).

*Curcuma aromatica* is the dry root of *Curcuma longa* L. (turmeric) that can be used as a spice or traditional medicine. According to Maeda *et al*[79], oral administration of *Curcuma aromatica* powder to rats led to a significant increase in bile secretion. Moreover, Wang *et al*[80] found that supplementing a lithogenic diet with 0.5% curcumin for 10 wk reduced the incidence of gallstone formation in young male mice to 26%, compared to 100% in the group fed with the lithogenic diet alone. Further, Li *et al*[81] found that curcumin can prevent the formation of cholesterol gallstones induced by a high-fat diet in mice by reducing the expression of Niemann-Pick C1-like 1 and sterol regulatory element binding transcription factor 2 at the mRNA and protein levels. Combining curcumin with piperine can also enhance its effectiveness by increasing its bioavailability. Some chemical components of *Curcuma zedoaria* , such as curcumin and gingeric acid, can play a role in improving bile flow and excretion by regulating gallbladder contraction and relaxation of biliary smooth muscle[82]. This is beneficial to the prevention or treatment of OJ, cholecystitis, and other diseases[83]. Yang *et al*[84] suggested that *Lysimachia christinae* Hance extracts (LCHE) exert excellent anti-cholecystitis effects and can alleviate lesion severity in a lithocholic acid-induced adult guinea pig model. Their study also revealed that LCHE can positively affect bile secretion, and a high dose of LCHE significantly enhanced bile secretion and bile emptying.

**Liver-protective herbs:** Liver-protective herbs help protect the liver and improve liver function. Examples include *Scutellaria baicalensis* (Huang Qin) and *Mori* *Fructus* (Sang Shen).

According to the experimental results presented by Jang *et al*[85], baicalin, the principal constituent of *Scutellaria baicalensis*, may offer protection against APAP-induced liver damage by blocking the biological activity of APAP-induced hepatotoxicity. This protective effect is thought to arise from the ability of baicalin to inhibit the expression of P450 family 2, subfamily E, and polypeptide 1. Liao *et al*[86] found that baicalin administration can effectively reduce liver damage induced by APAP. This protective effect is believed to be due to the down-regulation of the ERK signaling pathway and the subsequent reduction of its downstream inflammatory markers and microscopic changes. *Mori Fructus* polysaccharides (MFP) are large molecules extracted from *Mori Fructus*, which exhibit biological activity in terms of anti-liver damage. In a study conducted by Bian *et al*[87], MFP was found to regulate the metabolism of linoleic acid, alpha-linolenic acid, and glycerol phospholipids, thereby ameliorating acute alcoholic liver injury.

**Anti-inflammatory herbs:** Anti-inflammatory herbs help reduce inflammation in the liver and improve liver function. Examples include *Zingiber officinale* (Sheng Jiang)*, Fructus Schisandrae Chinensis* (Wu Weizi), and Semen Sojae Praepatum (Dan Douchi).

Grzanna *et al*[88] found that *Zingiber officinale* exerts its anti-inflammatory effects through multiple mechanisms. First, it suppresses prostaglandin synthesis by inhibiting both cyclooxygenase-1 and cyclooxygenase-2 enzymes. Second, ginger shares a similar property with NSAIDs in inhibiting prostaglandin synthesis. Additionally, some of the constituents present in ginger act as dual inhibitors of cyclooxygenase and lipoxygenase, which effectively reduces the biosynthesis of PG and leukotrienes. Li *et al*[89] found that *Fructus Schisandrae Chinensis* Fructus can significantly inhibit the expression of epidermal growth factor receptor (EGFR) in APAP-induced drug-induced liver injury (DILI). Moreover, stem cell factor also inhibits the expression of TNF-α, IL-6, and IL-1β, suggesting that it can regulate the inflammatory response to decelerate liver injury by modulating the EGFR signaling pathway. Fermented soya beans can affect the downstream targets of the NF-κB pathway*.* Fermented soy extract (FSE) can inhibit the expression of proinflammatory cytokines, including IL-1β, IL-6, IL-8, IL-12, TNF-α, and monocyte chemoattractant protein-1. This ultimately suppresses the exacerbation of inflammatory responses, as demonstrated in cell cultures or animal models challenged with various inflammation-promoting agents. Moreover, FSE can inhibit the binding of monocytes with endothelial cells after LPS induction, suggesting that FSE can prevent inflammatory cell-endothelial adherence and sentinel cell trafficking at the site of inflammation. Mouse models showed that FSE can limit the infiltration of immune cells, such as mast cells and macrophages, at the site of inflammation[90].

**Antioxidant herbs:** Antioxidant herbs help to reduce OS in the liver and protect liver cells from damage. Examples *Fructus Ligustri Lucidi* (Nv Zhenzi)*, Artemisiae Scopariae Herba* (Yin Chen)*, Fructus Schisandra chinensis* (Wu Weizi), *Taraxacum platycarpum Dahlst*. (Pu Gongying), and *Rhizoma Chuanxiong* (Chuan Xiong).

According to a previous study[91], *Fructus* *Ligustri Lucidi* treatment may prevent acute OS induced by BHT in rats. This was demonstrated by the reduction in concentrations of ALT, AST, ALP, and lactate dehydrogenase, as well as an increase in the levels of antioxidant enzymes in the liver, kidney, and lung. Yuan *et al*[92] proposed that *Artemisiae Scopariae Herba* has a potent hepatoprotective effect on APAP-induced liver injury in mice. The primary mechanisms underlying the protective effects of *Artemisiae Scopariae Herba* may include its alleviation of GSH depletion, inhibition of lipid peroxidation, and inactivation of caspase-8 and caspase-3 *via* inhibition of TNF-α, a pro-inflammatory mediator. Li *et al*[93] found that schisandrol A, which is the primary constituent of *Fructu Schisandra chinensiss*, can help treat DILI caused by APAP. This study suggested that the mechanism underlying this treatment is related to the activation of the TNF signaling pathway. Additionally, schisandrol A can play a significant role in treating DILI caused by APAP by reducing inflammation and OS while inhibiting the activities of cytochrome P450 enzymes. Qi *et al*[94] developed a procedure for rapid isolation of HO-1 inducers from *Rhizoma Chuanxiong* extract using bioactivity guidance. Their study revealed that senkyunolide-H and -I, two compounds isolated from the extract, induced HO-1 expression and inhibited lipid peroxidation and intracellular ROS formation. As a result, they enhanced cellular resistance to H2O2-induced cytotoxicity. A study conducted by Talapphet *et al*[95] found that *Taraxacum platycarpum Dahlst*., a commonly used drug in Korea, has the potential to promote Nrf2-mediated antioxidant activity by modulating the PI3K/Akt pathway. This natural remedy is often used to treat various ailments, such as mastitis, hepatitis, and jaundice. Moreover, the study revealed that the root extract of *Taraxacum platycarpum Dahlst*. can reduce alcohol-induced oxidative stress, while the leaf extract can alleviate fatty liver induced by a high-fat diet. Additionally, the flower extract of this plant was found to effectively remove ROS and prevent reactive oxygen damage. These findings suggest that *Taraxacum platycarpum Dahlst*. may have therapeutic potential in managing oxidative stress-related diseases. However, further research is needed to fully understand the mechanisms behind its antioxidant activity and its potential use as a treatment option.

**Chinese herbal compound:** Yinchenhao decoction (YCHD) is a TCM formula with a long history of use. It is derived from the Treatise on Exogenous Febrile Disease and is commonly used to treat damp-heat jaundice. The formula includes three main ingredients, *Artemisiae Scopariae Herba* (Yin Chen), *Gardeniae Fructus* (Zhi Zi), and *Radix Rhei et Rhizoma* (Da Huang). Through our previous research[96] using network pharmacology, we confirmed that YCHD can exert multi-component, multi-target, and multi-pathway functions. The respective mechanisms may be related to various biological processes, including anti-inflammatory, inhibition of liver fibrosis, antioxidant, and apoptosis. We demonstrated that YCHD can increase the expression of nuclear factor E2 related factor 2 (Nrf2), promote its translocation to the nucleus, reduce the overexpression of nitric oxide by regulating endothelin nitric oxide synthase and inducible nitric oxide synthase, and activate downstream GSH and NAD(P)H quinone dehydrogenase 1 expression, thereby protecting liver tissue from oxidative damage. Furthermore, YCHD can alleviate liver injury and oxidative damage, promote the translocation of Nrf2 to the nucleus, and upregulate the Nrf2 signaling pathway. Our research[97] revealed that OJ can lead to liver damage and apoptosis of hepatocytes. This is caused by the activation of the PERK-CHOP-GADD34 pathways and an increase in the Bax/Bcl-2 ratio. Further, we found that YCHD can improve liver functioning and reduce hepatocyte apoptosis through inhibiting the activation of the PERK-CHOP-GADD34 pathways and decreasing the Bax/Bcl-2 ratio. YCHD has been found to have a significant impact on various indicators, including sodium taurocholate cotransporting polypeptide, multidrug resistance protein 1, bile salt export pump, organic cation transporter 1, and organic anion transporter 1A2, leading to their increase. Furthermore, YCHD can regulate the main metabolic pathway of phase II, which inhibits the increase of naphthalene isothiocyanate content[98].

To sum up, herbal medicines may offer therapeutic benefits for OJ, especially when combined with modern medical treatments. Current evidence suggests that it can be a valuable complementary therapy in the management of this condition. Further research is needed to comprehensively assess the mechanisms of action and potential side effects of herbal medicines for this condition.

***Interventional and endoscopic treatment***

The surgical treatment of OJ depends on the cause, location, and severity of the obstruction. The causes of OJ include bile duct stones, tumors, and congenital anatomical abnormalities of the bile duct. Depending on the patient's condition, the obstruction can be relieved by biliary drainage, surgery, and endoscopic intervention.

**Percutaneous transhepatic cholangiodrainage and** **percutaneous transhepatic biliary stenting:** Percutaneous transhepatic cholangiodrainage (PTCD) is a common biliary drainage method used in clinical practice, mostly in patients with acute biliary obstruction that is more critical and needs to be treated as soon as possible, such as acute obstructive purulent cholangitis and acute obstructive cholecystitis. This method can rapidly alleviate the symptoms of biliary obstruction, allowing rapid reduction of jaundice and rapid recovery of liver functions. Mocan *et al*[99] studied 52 patients with HCCA, and the success rate of drainage in the PTCD-treated group was 88.46%, with significant recovery of liver function and fewer complications than before treatment. PTCD can also be used as preoperative preparation for surgical procedures to reduce intraoperative and postoperative complications. In patients with malignant cholestatic jaundice requiring surgery, the major adverse effects were markedly less frequent in the preoperative bile drainage group than in the direct surgery group[100]. If patients cannot undergo surgery due to their physical condition, or if the tumor is too large or has metastases that cannot be removed surgically, PTCD treatment can be used as a palliative treatment to relieve the symptoms of biliary obstruction. However, due to the risk of bleeding and hemobilia caused by jaundice and coagulopathy, PTCD procedures should be carefully monitored, and the tubes should be changed if they are left in place for an extended period of time. If they are not changed, there is a risk that they may fracture and leave foreign bodies inside the biliary tree, which can lead to the formation of a stone nidus or recurrent sepsis[101].

Percutaneous transhepatic biliary stenting (PTBS) is a minimally invasive procedure that is performed under local anesthesia, which greatly reduces the risk of complications, especially in high-risk patients[102]. Furthermore, this procedure has minimal side effects. The effectiveness of PTBS in managing both malignant and benign biliary strictures is remarkable, as it boasts a success rate of over 90%[103]. PTBS can be conducted as a standalone procedure to provide comprehensive biliary drainage or in conjunction with other treatment modalities such as chemotherapy or radiation[104]. According to a study, combining PTBS with 125I particles significantly lowers the odds of biliary re-obstruction and enhances survival rates when compared to PTBS alone, without raising the risk of postoperative complications[105]. Additionally, the findings of a multivariate analysis show that the combined treatment of PTBS and 125I particles is an independent significant factor for overall survival. The integration of these two treatments can reduce the likelihood of death by 74%[106]. Nevertheless, PTBS is technically challenging and requires the expertise of highly skilled interventional radiologists. Complications associated with PTBS include stent displacement, bleeding, and infection, which may necessitate further interventions. It is also worth mentioning that PTBS carries a greater risk of postoperative pancreatitis when compared to other biliary drainage methods[107,108].

**Endoscopic nasobiliary drainage:** With the continuous innovation of endoscopic technology, endoscopic nasobiliary drainage (ENBD) has been developed based on endoscopic retrograde cholangiopancreatography (ERCP). ENBD is a simple and easy approach for relieving biliary obstruction by reducing biliary pressure, thereby rapidly relieving the symptoms of biliary obstruction and controlling biliary infection[109,110]. However, it is important to note that the nasobiliary duct can irritate the throat, is prone to slippage or blockage, and has the disadvantage of removing abundant bile salts, which can further cause disorders of the water-electrolyte balance and digestive dysfunction in patients[111].

**Endoscopic retrograde biliary drainage:** Endoscopic retrograde biliary drainage has become a widespread method for the treatment of various benign and malignant biliary obstruction diseases. The conditions of patients with benign biliary strictures, such as primary sclerosing cholangitis, post-liver transplantation, post-cholecystectomy injury, chronic pancreatitis, and biliary immunoglobulin G4 involvement can be improved biliary stenting during ERCP. The purpose of placing the stents is to maintain the long-term patency of bile ducts[112]. Malignant biliary obstruction (MBO) can be classified as distal or hilar obstruction. In patients with malignant biliary obstruction and unresectable tumors, placement of a biliary stent can be considered palliative treatment. ERCP with stent placement is the most common treatment modality for unresectable distal MBO decompression, the treatment of which can significantly improve obstructive symptoms and improve the patient's quality of life[113]. Its role in the preoperative drainage of patients with surgically resectable tumors remains controversial. A retrospective analysis showed that preoperative biliary drainage reduced the risk of postoperative liver failure, but it failed to improve long-term survival[114]. Liu *et al*[115] concluded that preoperative drainage should not be routinely performed in patients with proximal bile duct cancer scheduled for surgical resection. The material of stents can be plastic or metal. Plastic stents must be replaced regularly every 12 months to keep the drainage open, however, they are less expensive. Placing a fully covered self-expanding metal stent is more expensive but it has a high success rate, easier insertion, and a high safety profile that can prevent tumor ingrowth[116]. A recent European guideline[117] strongly advocates the use of self-expandable metal stents (SEMS) over plastic stents for palliative drainage of distal MBO. This recommendation is due to the fact that SEMSs have been shown to lead to longer patient survival, lower risk of stent dysfunction/cholangitis, and reduced need for reinterventions. Additionally, the guideline suggests the use of uncovered SEMSs for palliative drainage of hilar MBO, which should ensure ≥ 50% drainage of liver volume. Several high-quality meta-analyses have explored the early selection of stent type (SEMS *vs* plastic)[118,119], and all have consistently demonstrated that SEMS placement is associated with a lower rate of re-intervention. The Archimedes stent is a novel biodegradable stent that shows promise for use in a range of surgical procedures, including liver transplantation and pancreaticoduodenectomy. Its use can help prevent bile leakage and improve patient outcomes[120,121]. A drug-eluting stent is a stent that has been coated with a medication that slowly releases over time. The coating on a drug-eluting stent can be made of various materials, such as polymers or metals, and the medication used can range from corticosteroids to anti-inflammatory drugs to chemotherapy agents. The medication helps to prevent scar tissue from forming around the stent, which can cause it to become blocked again[122].

**Endoscopic ultrasound-guided biliary drainage:** Some patients cannot undergo biliary stenting with ERCP because of anatomical difficulties arising from local infiltration of the malignancy. For example, when a tumor infiltrates the jugular abdomen and duodenal obstruction occurs, endoscopic ultrasound-guided biliary drainage (EUS-BD) may be an option as it allows better visualization of biliary obstruction and access to the bile duct through the gastrointestinal tract. EUS-BD techniques include EUS-guided rendezvous (RV), EUS-guided choledochoduodenostomy (CDS), and EUS-guided antegrade stenting (AS). Indications for EUS-RV include benign or potentially resectable malignant cases and unresectable malignant cases for which other EUS methods are not suited. A meta-analysis by Tsuchiya *et al*[123] showed that the overall success rate of EUS-RV was 81% and the complication rate was 10% in 382 EUS-RV cases. EUS-AS is frequently combined with hepatogastrostomy. EUS-AS includes EUS-guided antegrade stenting for malignant biliary obstruction and EUS-guided antegrade intervention for benign biliary diseases.

***Operative treatment***

The key aspect of OJ surgical treatment is to clarify the cause, location, and extent of the obstruction. The root cause of the obstruction must be identified as early as possible.

**Laparoscopic common bile duct exploration with cholecystectomy:** In cases of OJ associated with gallstones, different procedures are chosen depending on the site of the obstruction. Laparoscopic common bile duct exploration with cholecystectomy is widely regarded as an excellent surgical approach. The use of indocyanine green dye fluorescence cholangiogram is recommended as it allows for better exploration of the structure of the biliary system compared to traditional intraoperative cholangiogram[124,125]. Recent technological advancements, such as 3D technology and barbed sutures, have made laparoscopic common bile duct exploration safer and more feasible[126]. In the future, further technological development of cholangioscopy is crucial, particularly in improving the accuracy and visualization of cholangioscopy, as well as exploring the potential role of artificial intelligence in diagnosis[127].

**Pancreaticoduodenectomy:** Common surgical procedures for the treatment of OJ caused by malignant tumors of the bile ducts, duodeno-pancreas, and extrahepatic bile ducts invaded by hepatic peritonitis include pancreaticoduodenectomy, which can be done by open abdomen, laparoscopy or robotic surgery. Laparoscopic pancreaticoduodenectomy (LPD) has inherent advantages over open pancreaticoduodenectomy (OPD), including a clear visual field, lower bleeding, lower pain intensity, and faster recovery for individuals, particularly in the elderly. Patients with malignant tumors undergo surgery with the primary outcome measure being long-term survival, which serves as a fundamental purpose. Croome *et al*[128] compared overall survival and disease-free survival in two groups of patients with pancreatic ductal adenocarcinoma who underwent different surgical procedures. They found no significant differences in overall survival between the 108 cases in the LPD group and the 214 cases in the OPD group, but the LPD group had a higher disease-free survival rate. Similarly, Kantor *et al*[129] compared the overall survival of 828 LPD cases and 7385 OPD cases in the United States National Cancer Database from 2010 to 2013 and found no significant differences between the two groups (20.7 months compared to 20.9 mo). However, there is currently a lack of prospective multicenter randomized controlled trials studying the long-term survival of patients with malignant tumors treated with LPD and OPD.

**Roux-Y choledochojejunostomy:** At the time of initial diagnosis, some patients have already progressed to intermediate and advanced stages, thus having missed the optimal time for radical surgery, thus leaving palliative surgical treatment the proper option. When biliary lesions cause obstructive biliary strictures, the lesions can be surgically removed, and the bile ducts can be anastomosed to the jejunum to reconstruct the physiology of the bile duct and drain the bile. This procedure is termed Roux-Y choledochojejunostomy, which can better preserve the integrity of the intestinal canal and maintain the normal physiological function of the intestine, and the probability of recurrence of biliary stricture after surgery is lower[130]. External T-tube drainage and internal bile-intestinal drainage are suitable for patients of advanced age who cannot undergo prolonged surgery. It has the advantages of minimal surgical trauma, easy operation, and rapid postoperative recovery. However, this review excludes pediatric population issues.

**CONCLUSION**

The treatment of OJ depends on the underlying cause, and as such, it is crucial to identify the cause of the obstruction to provide appropriate treatment. Currently, surgical intervention remains the primary approach for treating OJ. However, perioperative complications associated with OJ also require comprehensive treatment. In addition to modern medical treatments, herbal medicines may offer therapeutic benefits for patients with OJ. Combining herbal medicine with modern medical treatments can thus be particularly effective for managing this condition.

**REFERENCES**

1 **Chen HL**, Wu SH, Hsu SH, Liou BY, Chen HL, Chang MH. Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases. *J Biomed Sci* 2018; **25**: 75 [PMID: 30367658 DOI: 10.1186/s12929-018-0475-8]

2 **Rodrigues Santos L**, Silva Cruz M, Veiga Ferraz R, Ferraz Moreira V, Castro A. Jaundice as a Rare Manifestation of Epstein-Barr Virus Primary Infection. *Cureus* 2021; **13**: e15609 [PMID: 34277228 DOI: 10.7759/cureus.15609]

3 **Abolurin OO**, Senbanjo IO, Adekoya AO, Ajibola ED. Congenital cytomegalovirus infection as an important cause of infantile cholestatic jaundice: a case report. *Pan Afr Med J* 2020; **36**: 106 [PMID: 32821317 DOI: 10.11604/pamj.2020.36.106.20577]

4 **Perez A**, Kogan-Liberman D, Sheflin-Findling S, Raizner A, Ahuja KL, Ovchinsky N. Presentation of Severe Acute Respiratory Syndrome-Coronavirus 2 Infection as Cholestatic Jaundice in Two Healthy Adolescents. *J Pediatr* 2020; **226**: 278-280 [PMID: 32710910 DOI: 10.1016/j.jpeds.2020.07.054]

5 **Vij M**, Rela M. Biliary atresia: pathology, etiology and pathogenesis. *Future Sci OA* 2020; **6**: FSO466 [PMID: 32518681 DOI: 10.2144/fsoa-2019-0153]

6 **Pandya G**, Dixit R, Shelat V, Dixit K, Shah N, Shah K. Obstructive jaundice: a manifestation of pancreatic tuberculosis. *J Indian Med Assoc* 2007; **105**: 133-134, 136 [PMID: 17824465]

7 **Kwan KEL**, Shelat VG, Tan CH. Recurrent pyogenic cholangitis: a review of imaging findings and clinical management. *Abdom Radiol (NY)* 2017; **42**: 46-56 [PMID: 27770158 DOI: 10.1007/s00261-016-0953-y]

8 **Wu R**, Zou X, Zhang B. A Rare Cause of Obstructive Jaundice. *Gastroenterology* 2023; **164**: e5-e8 [PMID: 36372221 DOI: 10.1053/j.gastro.2022.10.035]

9 **Li ZM**, Jiao DC, Han XW, Lei QY, Zhou XL, Xu M. Preliminary application of brachytherapy with double-strand (125)I seeds and biliary drainage for malignant obstructive jaundice. *Surg Endosc* 2022; **36**: 4932-4938 [PMID: 34845555 DOI: 10.1007/s00464-021-08848-6]

10 **Ikarashi D**, Tamada S, Tsuyukubo T, Ono S, Fujisawa H, Obara W. Advance renal pelvic cancer caused obstructive jaundice: A case report. *Urol Case Rep* 2022; **43**: 102080 [PMID: 35497506 DOI: 10.1016/j.eucr.2022.102080]

11 **Balogun OS**, Atoyebi OA. Management of Malignant Obstructive Jaundice: Defining the Relevance of Various Palliative Surgical Options in Resource-Challenged Settings: A Review Article. *J West Afr Coll Surg* 2022; **12**: 111-119 [PMID: 36388748]

12 **Lucas WB**, Chuttani R. Pathophysiology and current concepts in the diagnosis of obstructive jaundice. *Gastroenterologist* 1995; **3**: 105-118 [PMID: 7640942]

13 **Wang L**, Yu WF. Obstructive jaundice and perioperative management. *Acta Anaesthesiol Taiwan* 2014; **52**: 22-29 [PMID: 24999215 DOI: 10.1016/j.aat.2014.03.002]

14 **Li J**, Zhuo S, Chen B, Liu Y, Wu H. Clinical efficacy of laparoscopic modified loop cholecystojejunostomy for the treatment of malignant obstructive jaundice. *J Int Med Res* 2020; **48**: 300060519866285 [PMID: 31547725 DOI: 10.1177/0300060519866285]

15 **Modha K**. Clinical Approach to Patients With Obstructive Jaundice. *Tech Vasc Interv Radiol* 2015; **18**: 197-200 [PMID: 26615159 DOI: 10.1053/j.tvir.2015.07.002]

16 **Rizzo A**, Ricci AD, Frega G, Palloni A, DE Lorenzo S, Abbati F, Mollica V, Tavolari S, DI Marco M, Brandi G. How to Choose Between Percutaneous Transhepatic and Endoscopic Biliary Drainage in Malignant Obstructive Jaundice: An Updated Systematic Review and Meta-analysis. *In Vivo* 2020; **34**: 1701-1714 [PMID: 32606139 DOI: 10.21873/invivo.11964]

17 **Celikkaya ME**, Akcora B, Hakverdi S, Ozer B, Ulutas KT, Duran N. Effects of Probiotic Use on Bacterial Translocation in Created Rat Models with Biliary Obstructions. *Eurasian J Med* 2019; **51**: 106-111 [PMID: 31258347 DOI: 10.5152/eurasianjmed.2019.18426]

18 **Sartelli M**, Weber DG, Ruppé E, Bassetti M, Wright BJ, Ansaloni L, Catena F, Coccolini F, Abu-Zidan FM, Coimbra R, Moore EE, Moore FA, Maier RV, De Waele JJ, Kirkpatrick AW, Griffiths EA, Eckmann C, Brink AJ, Mazuski JE, May AK, Sawyer RG, Mertz D, Montravers P, Kumar A, Roberts JA, Vincent JL, Watkins RR, Lowman W, Spellberg B, Abbott IJ, Adesunkanmi AK, Al-Dahir S, Al-Hasan MN, Agresta F, Althani AA, Ansari S, Ansumana R, Augustin G, Bala M, Balogh ZJ, Baraket O, Bhangu A, Beltrán MA, Bernhard M, Biffl WL, Boermeester MA, Brecher SM, Cherry-Bukowiec JR, Buyne OR, Cainzos MA, Cairns KA, Camacho-Ortiz A, Chandy SJ, Che Jusoh A, Chichom-Mefire A, Colijn C, Corcione F, Cui Y, Curcio D, Delibegovic S, Demetrashvili Z, De Simone B, Dhingra S, Diaz JJ, Di Carlo I, Dillip A, Di Saverio S, Doyle MP, Dorj G, Dogjani A, Dupont H, Eachempati SR, Enani MA, Egiev VN, Elmangory MM, Ferrada P, Fitchett JR, Fraga GP, Guessennd N, Giamarellou H, Ghnnam W, Gkiokas G, Goldberg SR, Gomes CA, Gomi H, Guzmán-Blanco M, Haque M, Hansen S, Hecker A, Heizmann WR, Herzog T, Hodonou AM, Hong SK, Kafka-Ritsch R, Kaplan LJ, Kapoor G, Karamarkovic A, Kees MG, Kenig J, Kiguba R, Kim PK, Kluger Y, Khokha V, Koike K, Kok KY, Kong V, Knox MC, Inaba K, Isik A, Iskandar K, Ivatury RR, Labbate M, Labricciosa FM, Laterre PF, Latifi R, Lee JG, Lee YR, Leone M, Leppaniemi A, Li Y, Liang SY, Loho T, Maegele M, Malama S, Marei HE, Martin-Loeches I, Marwah S, Massele A, McFarlane M, Melo RB, Negoi I, Nicolau DP, Nord CE, Ofori-Asenso R, Omari AH, Ordonez CA, Ouadii M, Pereira Júnior GA, Piazza D, Pupelis G, Rawson TM, Rems M, Rizoli S, Rocha C, Sakakushev B, Sanchez-Garcia M, Sato N, Segovia Lohse HA, Sganga G, Siribumrungwong B, Shelat VG, Soreide K, Soto R, Talving P, Tilsed JV, Timsit JF, Trueba G, Trung NT, Ulrych J, van Goor H, Vereczkei A, Vohra RS, Wani I, Uhl W, Xiao Y, Yuan KC, Zachariah SK, Zahar JR, Zakrison TL, Corcione A, Melotti RM, Viscoli C, Viale P. Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). *World J Emerg Surg* 2016; **11**: 33 [PMID: 27429642 DOI: 10.1186/s13017-016-0089-y]

19 **Zhang P**, Jiang N, Xu L, Shen Z, Liu X, Cai X. Clostridium perfringens and Escherichia coli Bacteremia in a Patient with Acute Obstructive Suppurative Cholangitis: A Case Report and Review of the Literature. *Am J Case Rep* 2022; **23**: e936329 [PMID: 35526110 DOI: 10.12659/AJCR.936329]

20 **Jorge GD**, Tártaro RR, Escanhoela CA, Boin ID. Long-Time Choledochal Clamping in Wistar Rats Causes Biliary Obstruction Progressing to Hepatic Fibrosis. *Transplant Proc* 2016; **48**: 2375-2378 [PMID: 27742301 DOI: 10.1016/j.transproceed.2016.06.011]

21 **Margaritis VG**, Filos KS, Michalaki MA, Scopa CD, Spiliopoulou I, Nikolopoulou VN, Vagianos CE. Effect of oral glutamine administration on bacterial tanslocation, endotoxemia, liver and ileal morphology, and apoptosis in rats with obstructive jaundice. *World J Surg* 2005; **29**: 1329-1334 [PMID: 16136290 DOI: 10.1007/s00268-005-7721-4]

22 **Ozozan OV**, Dinc T, Vural V, Ozogul C, Ozmen MM, Coskun F. An electron microscopy study of liver and kidney damage in an experimental model of obstructive jaundice. *Ann Ital Chir* 2020; **91**: 122-130 [PMID: 32180577]

23 **Luo WW**, Zhou XL, Wang QQ, Shao YJ, Li ZM, Zhao DK, Yu SP. The application of Compont gel in chronic obstructive jaundice rats model. *Acta Cir Bras* 2019; **34**: e201900504 [PMID: 31166460 DOI: 10.1590/s0102-865020190050000004]

24 **Zhang M**, Wang XQ, Zhou YK, Ma YL, Shen TY, Chen HQ, Chu ZX, Qin HL. Effects of oral Lactobacillus plantarum on hepatocyte tight junction structure and function in rats with obstructive jaundice. *Mol Biol Rep* 2010; **37**: 2989-2999 [PMID: 19816788 DOI: 10.1007/s11033-009-9866-y]

25 **Montilla P**, Cruz A, Padillo FJ, Túnez I, Gascon F, Muñoz MC, Gómez M, Pera C. Melatonin versus vitamin E as protective treatment against oxidative stress after extra-hepatic bile duct ligation in rats. *J Pineal Res* 2001; **31**: 138-144 [PMID: 11555169 DOI: 10.1034/j.1600-079x.2001.310207.x]

26 **Yoshidome H**, Miyazaki M, Shimizu H, Ito H, Nakagawa K, Ambiru S, Nakajima N, Edwards MJ, Lentsch AB. Obstructive jaundice impairs hepatic sinusoidal endothelial cell function and renders liver susceptible to hepatic ischemia/reperfusion. *J Hepatol* 2000; **33**: 59-67 [PMID: 10905587 DOI: 10.1016/s0168-8278(00)80160-9]

27 **Lu Y**, Zhang BY, Zhao C, Jin X. Effect of obstructive jaundice on hemodynamics in the liver and its clinical significance. *Hepatobiliary Pancreat Dis Int* 2009; **8**: 494-497 [PMID: 19822492]

28 **Ciesielska A**, Matyjek M, Kwiatkowska K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. *Cell Mol Life Sci* 2021; **78**: 1233-1261 [PMID: 33057840 DOI: 10.1007/s00018-020-03656-y]

29 **Koutelidakis I**, Papaziogas B, Giamarellos-Bourboulis EJ, Makris J, Pavlidis T, Giamarellou H, Papaziogas T. Systemic endotoxaemia following obstructive jaundice: the role of lactulose. *J Surg Res* 2003; **113**: 243-247 [PMID: 12957136 DOI: 10.1016/s0022-4804(03)00209-9]

30 **Thompson JN**, Blumgart LH. Endotoxaemia in obstructive jaundice. *Br J Surg* 1984; **71**: 247-248 [PMID: 6697137 DOI: 10.1002/bjs.1800710336]

31 **Pavlidis ET**, Pavlidis TE. Pathophysiological consequences of obstructive jaundice and perioperative management. *Hepatobiliary Pancreat Dis Int* 2018; **17**: 17-21 [PMID: 29428098 DOI: 10.1016/j.hbpd.2018.01.008]

32 **Stupin V**, Abramov I, Gahramanov T, Kovalenko A, Manturova N, Litvitskiy P, Balkizov Z, Silina E. Comparative Study of the Results of Operations in Patients with Tumor and Non-Tumor Obstructive Jaundice Who Received and Did Not Receive Antioxidant Therapy for the Correction of Endotoxemia, Glycolysis, and Oxidative Stress. *Antioxidants (Basel)* 2022; **11** [PMID: 35740100 DOI: 10.3390/antiox11061203]

33 **Mairiang P**, Bhudhisawasdi V, Borirakchanyavat V, Sitprija V. Acute renal failure in obstructive jaundice in cholangiocarcinoma. *Arch Intern Med* 1990; **150**: 2357-2360 [PMID: 2173511]

34 **Wang Y**, Liu JG, Han JL. Downregulation of AQP2 and AQP2 mRNA expression in kidney medulla of rats with bile duct ligation. *Hepatobiliary Pancreat Dis Int* 2007; **6**: 636-640 [PMID: 18086632]

35 **Jayarajah U**, Basnayake O, Wijerathne PK, Sivaganesh S. Acute kidney injury due to high-output external biliary drainage in a patient with malignant obstructive jaundice: a case report. *J Med Case Rep* 2019; **13**: 251 [PMID: 31405371 DOI: 10.1186/s13256-019-2195-4]

36 **Fickert P**, Krones E, Pollheimer MJ, Thueringer A, Moustafa T, Silbert D, Halilbasic E, Yang M, Jaeschke H, Stokman G, Wells RG, Eller K, Rosenkranz AR, Eggertsen G, Wagner CA, Langner C, Denk H, Trauner M. Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice. *Hepatology* 2013; **58**: 2056-2069 [PMID: 23813550 DOI: 10.1002/hep.26599]

37 **Krones E**, Eller K, Pollheimer MJ, Racedo S, Kirsch AH, Frauscher B, Wahlström A, Ståhlman M, Trauner M, Grahammer F, Huber TB, Wagner K, Rosenkranz AR, Marschall HU, Fickert P. NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice. *J Hepatol* 2017; **67**: 110-119 [PMID: 28242240 DOI: 10.1016/j.jhep.2017.02.019]

38 **Houdijk AP**, van Lambalgen AA, Thijs LG, van Leeuwen PA. Gut endotoxin restriction improves postoperative hemodynamics in the bile duct-ligated rat. *Shock* 1998; **9**: 282-288 [PMID: 9565257 DOI: 10.1097/00024382-199804000-00008]

39 **Wang L**, Zhai YQ, Xu LL, Qiao C, Sun XL, Ding JH, Lu M, Hu G. Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice. *Exp Neurol* 2014; **251**: 22-29 [PMID: 24220636 DOI: 10.1016/j.expneurol.2013.11.001]

40 **Wakui N**, Takeda Y, Nishinakagawa S, Ueki N, Otsuka T, Oba N, Hashimoto H, Kamiyama N, Sumino Y, Kojima T. Effect of obstructive jaundice on hepatic hemodynamics: use of Sonazoid-enhanced ultrasonography in a prospective study of the blood flow balance between the hepatic portal vein and hepatic artery. *J Med Ultrason (2001)* 2015; **42**: 513-520 [PMID: 26576976 DOI: 10.1007/s10396-015-0629-1]

41 **Clarke NE**, Turner AJ. Angiotensin-converting enzyme 2: the first decade. *Int J Hypertens* 2012; **2012**: 307315 [PMID: 22121476 DOI: 10.1155/2012/307315]

42 **Naranjo A**, Cruz A, López P, Chicano M, Martín-Malo A, Sitges-Serra A, Muntané J, Padillo J. Renal function after dopamine and fluid administration in patients with malignant obstructive jaundice. A prospective randomized study. *J Gastrointestin Liver Dis* 2011; **20**: 161-167 [PMID: 21725513]

43 **Martínez-Cecilia D**, Reyes-Díaz M, Ruiz-Rabelo J, Gomez-Alvarez M, Villanueva CM, Álamo J, Muntané J, Padillo FJ. Oxidative stress influence on renal dysfunction in patients with obstructive jaundice: A case and control prospective study. *Redox Biol* 2016; **8**: 160-164 [PMID: 26774750 DOI: 10.1016/j.redox.2015.12.009]

44 **Zhou X**, Cheung CM, Yang JM, Or PM, Lee WY, Yeung JH. Danshen (Salvia miltiorrhiza) water extract inhibits paracetamol-induced toxicity in primary rat hepatocytes via reducing CYP2E1 activity and oxidative stress. *J Pharm Pharmacol* 2015; **67**: 980-989 [PMID: 25645193 DOI: 10.1111/jphp.12381]

45 **Kawarabayashi N**, Seki S, Hatsuse K, Kinoshita M, Takigawa T, Tsujimoto H, Kawabata T, Nakashima H, Shono S, Mochizuki H. Immunosuppression in the livers of mice with obstructive jaundice participates in their susceptibility to bacterial infection and tumor metastasis. *Shock* 2010; **33**: 500-506 [PMID: 19823116 DOI: 10.1097/SHK.0b013e3181c4e44a]

46 **Yang R**, Zhu S, Pischke SE, Haugaa H, Zou X, Tonnessen TI. Bile and circulating HMGB1 contributes to systemic inflammation in obstructive jaundice. *J Surg Res* 2018; **228**: 14-19 [PMID: 29907203 DOI: 10.1016/j.jss.2018.02.049]

47 **Xu L**, Ge F, Hu Y, Yu Y, Guo K, Miao C. Sevoflurane Postconditioning Attenuates Hepatic Ischemia-Reperfusion Injury by Limiting HMGB1/TLR4/NF-κB Pathway via Modulating microRNA-142 in vivo and in vitro. *Front Pharmacol* 2021; **12**: 646307 [PMID: 33935744 DOI: 10.3389/fphar.2021.646307]

48 **Luo L**, Yao Y, Liao H, Huang J, Liao M, Wang J, Yuan K, Zeng Y. Cumulative damage effect of jaundice may be an effective predictor of complications in patients undergoing radical resection of Bismuth type II or above hilar cholangiocarcinoma. *Ann Transl Med* 2021; **9**: 861 [PMID: 34164495 DOI: 10.21037/atm-21-1860]

49 **Xiao Y**, Hang Y, Chen Y, Fang X, Cao X, Hu X, Luo H, Zhu H, Zhu W, Zhong Q, Hu L. A Retrospective Analysis of Risk Factors and Patient Outcomes of Bloodstream Infection with Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Chinese Tertiary Hospital. *Infect Drug Resist* 2020; **13**: 4289-4296 [PMID: 33262623 DOI: 10.2147/IDR.S269989]

50 **Zhang J**, Yu M, Liu B, Zhou P, Zuo N, Wang Y, Feng Y, Zhang Y, Wang J, He Y, Wu Y, Dong Z, Hong L, Shi J. Neutrophil extracellular traps enhance procoagulant activity and thrombotic tendency in patients with obstructive jaundice. *Liver Int* 2021; **41**: 333-347 [PMID: 33159371 DOI: 10.1111/liv.14725]

51 **Cakir T**, Cingi A, Yeğen C. Coagulation dynamics and platelet functions in obstructive jaundiced patients. *J Gastroenterol Hepatol* 2009; **24**: 748-751 [PMID: 19646016 DOI: 10.1111/j.1440-1746.2009.05801.x]

52 **Prentice CR**. Acquired coagulation disorders. *Clin Haematol* 1985; **14**: 413-442 [PMID: 3899441]

53 **Hunt DR**, Allison ME, Prentice CR, Blumgart LH. Endotoxemia, disturbance of coagulation, and obstructive jaundice. *Am J Surg* 1982; **144**: 325-329 [PMID: 7114371 DOI: 10.1016/0002-9610(82)90011-3]

54 **Papadopoulos V**, Filippou D, Manolis E, Mimidis K. Haemostasis impairment in patients with obstructive jaundice. *J Gastrointestin Liver Dis* 2007; **16**: 177-186 [PMID: 17592568]

55 **Lillemoe KD**, Pitt HA. Palliation. Surgical and otherwise. *Cancer* 1996; **78**: 605-614 [PMID: 8681299]

56 **Pain JA**, Cahill CJ, Bailey ME. Perioperative complications in obstructive jaundice: therapeutic considerations. *Br J Surg* 1985; **72**: 942-945 [PMID: 3936565 DOI: 10.1002/bjs.1800721203]

57 **Risser A**, Donovan D, Heintzman J, Page T. NSAID prescribing precautions. *Am Fam Physician* 2009; **80**: 1371-1378 [PMID: 20000300]

58 **Evenepoel P**. Acute toxic renal failure. *Best Pract Res Clin Anaesthesiol* 2004; **18**: 37-52 [PMID: 14760873 DOI: 10.1016/j.bpa.2003.09.007]

59 **Perone JA**, Riall TS, Olino K. Palliative Care for Pancreatic and Periampullary Cancer. *Surg Clin North Am* 2016; **96**: 1415-1430 [PMID: 27865285 DOI: 10.1016/j.suc.2016.07.012]

60 **Hadano Y**, Hijikata T. A fatal case of persistent bacteremia and acute cholecystitis caused by Staphylococcus aureus: A case report. *IDCases* 2023; **31**: e01695 [PMID: 36704024 DOI: 10.1016/j.idcr.2023.e01695]

61 **Wolloch Y**, Feigenberg Z, Zer M, Dintsman M. The influence of biliary infection on the postoperative course after biliary tract surgery. *Am J Gastroenterol* 1977; **67**: 456-462 [PMID: 900109]

62 **Gomi H**, Solomkin JS, Schlossberg D, Okamoto K, Takada T, Strasberg SM, Ukai T, Endo I, Iwashita Y, Hibi T, Pitt HA, Matsunaga N, Takamori Y, Umezawa A, Asai K, Suzuki K, Han HS, Hwang TL, Mori Y, Yoon YS, Huang WS, Belli G, Dervenis C, Yokoe M, Kiriyama S, Itoi T, Jagannath P, Garden OJ, Miura F, de Santibañes E, Shikata S, Noguchi Y, Wada K, Honda G, Supe AN, Yoshida M, Mayumi T, Gouma DJ, Deziel DJ, Liau KH, Chen MF, Liu KH, Su CH, Chan ACW, Yoon DS, Choi IS, Jonas E, Chen XP, Fan ST, Ker CG, Giménez ME, Kitano S, Inomata M, Mukai S, Higuchi R, Hirata K, Inui K, Sumiyama Y, Yamamoto M. Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. *J Hepatobiliary Pancreat Sci* 2018; **25**: 3-16 [PMID: 29090866 DOI: 10.1002/jhbp.518]

63 **Ahmed M**. Acute cholangitis - an update. *World J Gastrointest Pathophysiol* 2018; **9**: 1-7 [PMID: 29487761 DOI: 10.4291/wjgp.v9.i1.1]

64 **Mohan R**, Wei Lynn Goh S, Tan GW, Tan YP, Junnarkar SP, Huey CWT, Low JK, Shelat VG. Validation of Tokyo Guidelines 2007 and Tokyo Guidelines 2013/2018 Criteria for Acute Cholangitis and Predictors of In-Hospital Mortality. *Visc Med* 2021; **37**: 434-442 [PMID: 34722727 DOI: 10.1159/000516424]

65 **Thabit AK**. Antibiotics in the Biliary Tract: A Review of the Pharmacokinetics and Clinical Outcomes of Antibiotics Penetrating the Bile and Gallbladder Wall. *Pharmacotherapy* 2020; **40**: 672-691 [PMID: 32485056 DOI: 10.1002/phar.2431]

66 **Roila F**, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. *Ann Oncol* 2016; **27**: v119-v133 [PMID: 27664248 DOI: 10.1093/annonc/mdw270]

67 **Beuers U**, Wolters F, Oude Elferink RPJ. Mechanisms of pruritus in cholestasis: understanding and treating the itch. *Nat Rev Gastroenterol Hepatol* 2023; **20**: 26-36 [PMID: 36307649 DOI: 10.1038/s41575-022-00687-7]

68 **Kondrackiene J**, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. *Gastroenterology* 2005; **129**: 894-901 [PMID: 16143129 DOI: 10.1053/j.gastro.2005.06.019]

69 **Khurana S**, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. *Liver Int* 2006; **26**: 943-948 [PMID: 16953834 DOI: 10.1111/j.1478-3231.2006.01326.x]

70 **Mayo MJ**, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. *Hepatology* 2007; **45**: 666-674 [PMID: 17326161 DOI: 10.1002/hep.21553]

71 **Düll MM**, Wolf K, Vetter M, Dietrich P, Neurath MF, Kremer AE. Endogenous Opioid Levels Do Not Correlate With Itch Intensity and Therapeutic Interventions in Hepatic Pruritus. *Front Med (Lausanne)* 2021; **8**: 641163 [PMID: 33937284 DOI: 10.3389/fmed.2021.641163]

72 **Müller C**, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, Raderer M, Scheithauer W, Ferenci P. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. *Eur J Gastroenterol Hepatol* 1998; **10**: 865-870 [PMID: 9831410 DOI: 10.1097/00042737-199810000-00010]

73 **Decock S**, Roelandts R, Steenbergen WV, Laleman W, Cassiman D, Verslype C, Fevery J, Pelt JV, Nevens F. Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study. *J Hepatol* 2012; **57**: 637-641 [PMID: 22613002 DOI: 10.1016/j.jhep.2012.04.023]

74 **Liu F**, Chen Y, Yang C. The indocyanine-green retention test combined with nutritional-risk screening can accurately assess nutritional status of patients with malignant obstructive jaundice. *Asian J Surg* 2023; **46**: 2217-2218 [PMID: 36577581 DOI: 10.1016/j.asjsur.2022.11.109]

75 **Yao J**, Kong Y, Wang C, Wei Y, Li H, Liu C. Endobiliary Ablation Combined with Immune Nutrition Improves Quality of Life: A Preliminary Clinical Study in Patients with Advanced Malignant Obstructive Jaundice. *Med Sci Monit* 2022; **28**: e936863 [PMID: 36104943 DOI: 10.12659/MSM.936863]

76 **Sun Y**, Yang Z, Tan H. Perioperative nutritional support and fluid therapy in patients with liver diseases. *Hepatobiliary Surg Nutr* 2014; **3**: 140-148 [PMID: 25019075 DOI: 10.3978/j.issn.2304-3881.2014.04.05]

77 **Nakakura EK**, Warren RS. Palliative care for patients with advanced pancreatic and biliary cancers. *Surg Oncol* 2007; **16**: 293-297 [PMID: 17855076 DOI: 10.1016/j.suronc.2007.08.003]

78 **Roberts KJ**, Schrem H, Hodson J, Angelico R, Dasari BVM, Coldham CA, Marudanayagam R, Sutcliffe RP, Muiesan P, Isaac J, Mirza DF. Pancreas exocrine replacement therapy is associated with increased survival following pancreatoduodenectomy for periampullary malignancy. *HPB (Oxford)* 2017; **19**: 859-867 [PMID: 28711377 DOI: 10.1016/j.hpb.2017.05.009]

79 **Maeda H**, Sunagane N, Kubota K. [Pharmacological effects of the powder from Curucuma zedoaria Roscoe on the gastrointestinal tract of experimental animals]. *Yakugaku Zasshi* 1984; **104**: 640-643 [PMID: 6542138 DOI: 10.1248/yakushi1947.104.6\_640]

80 **Wang DQ**, Zhang L, Wang HH. High cholesterol absorption efficiency and rapid biliary secretion of chylomicron remnant cholesterol enhance cholelithogenesis in gallstone-susceptible mice. *Biochim Biophys Acta* 2005; **1733**: 90-99 [PMID: 15749059 DOI: 10.1016/j.bbalip.2004.12.005]

81 **Li Y**, Li M, Wu S, Tian Y. Combination of curcumin and piperine prevents formation of gallstones in C57BL6 mice fed on lithogenic diet: whether NPC1L1/SREBP2 participates in this process? *Lipids Health Dis* 2015; **14**: 100 [PMID: 26335572 DOI: 10.1186/s12944-015-0106-2]

82 **Lobo R**, Prabhu KS, Shirwaikar A, Shirwaikar A. Curcuma zedoaria Rosc. (white turmeric): a review of its chemical, pharmacological and ethnomedicinal properties. *J Pharm Pharmacol* 2009; **61**: 13-21 [PMID: 19126292 DOI: 10.1211/jpp/61.01.0003]

83 **Zheng L**, Ji YY, Dai YC, Wen XL, Wu SC. Network pharmacology and molecular docking reveal zedoary turmeric-trisomes in Inflammatory bowel disease with intestinal fibrosis. *World J Clin Cases* 2022; **10**: 7674-7685 [PMID: 36158488 DOI: 10.12998/wjcc.v10.i22.7674]

84 **Yang X**, Wang BC, Zhang X, Liu WQ, Qian JZ, Li W, Deng J, Singh GK, Su H. Evaluation of Lysimachia christinae Hance extracts as anticholecystitis and cholagogic agents in animals. *J Ethnopharmacol* 2011; **137**: 57-63 [PMID: 21524697 DOI: 10.1016/j.jep.2011.04.029]

85 **Jang SI**, Kim HJ, Hwang KM, Jekal SJ, Pae HO, Choi BM, Yun YG, Kwon TO, Chung HT, Kim YC. Hepatoprotective effect of baicalin, a major flavone from Scutellaria radix, on acetaminophen-induced liver injury in mice. *Immunopharmacol Immunotoxicol* 2003; **25**: 585-594 [PMID: 14686800 DOI: 10.1081/iph-120026443]

86 **Liao CC**, Day YJ, Lee HC, Liou JT, Chou AH, Liu FC. ERK Signaling Pathway Plays a Key Role in Baicalin Protection Against Acetaminophen-Induced Liver Injury. *Am J Chin Med* 2017; **45**: 105-121 [PMID: 28081632 DOI: 10.1142/S0192415X17500082]

87 **Bian L**, Chen HG, Gong XJ, Zhao C, Zhou X. Mori Fructus Polysaccharides Attenuate Alcohol-Induced Liver Damage by Regulating Fatty Acid Synthesis, Degradation and Glycerophospholipid Metabolism in Mice. *Front Pharmacol* 2021; **12**: 766737 [PMID: 34744745 DOI: 10.3389/fphar.2021.766737]

88 **Grzanna R**, Lindmark L, Frondoza CG. Ginger--an herbal medicinal product with broad anti-inflammatory actions. *J Med Food* 2005; **8**: 125-132 [PMID: 16117603 DOI: 10.1089/jmf.2005.8.125]

89 **Li X**, Li M, Deng S, Yu T, Ma Y, Yang H, Zhang J, Zheng Y, Ma L. A network pharmacology-integrated metabolomics strategy for clarifying the action mechanisms of Schisandrae Chinensis Fructus for treating drug-induced liver injury by acetaminophen. *Bioorg Med Chem* 2021; **31**: 115992 [PMID: 33421914 DOI: 10.1016/j.bmc.2020.115992]

90 **Das D**, Sarkar S, Borsingh Wann S, Kalita J, Manna P. Current perspectives on the anti-inflammatory potential of fermented soy foods. *Food Res Int* 2022; **152**: 110922 [PMID: 35181093 DOI: 10.1016/j.foodres.2021.110922]

91 **Lin HM**, Yen FL, Ng LT, Lin CC. Protective effects of Ligustrum lucidum fruit extract on acute butylated hydroxytoluene-induced oxidative stress in rats. *J Ethnopharmacol* 2007; **111**: 129-136 [PMID: 17157464 DOI: 10.1016/j.jep.2006.11.004]

92 **Yuan HD**, Jin GZ, Piao GC. Hepatoprotective effects of an active part from Artemisia sacrorum Ledeb. against acetaminophen-induced toxicity in mice. *J Ethnopharmacol* 2010; **127**: 528-533 [PMID: 19833181 DOI: 10.1016/j.jep.2009.10.002]

93 **Li X**, Ge J, Li M, Deng S, Li J, Ma Y, Zhang J, Zheng Y, Ma L. Network pharmacology, molecular docking technology integrated with pharmacodynamic study to reveal the potential targets of Schisandrol A in drug-induced liver injury by acetaminophen. *Bioorg Chem* 2022; **118**: 105476 [PMID: 34788696 DOI: 10.1016/j.bioorg.2021.105476]

94 **Qi H**, Siu SO, Chen Y, Han Y, Chu IK, Tong Y, Lau AS, Rong J. Senkyunolides reduce hydrogen peroxide-induced oxidative damage in human liver HepG2 cells via induction of heme oxygenase-1. *Chem Biol Interact* 2010; **183**: 380-389 [PMID: 19961840 DOI: 10.1016/j.cbi.2009.11.029]

95 **Talapphet N**, Palanisamy S, Li C, Ma N, Prabhu NM, You S. Polysaccharide extracted from Taraxacum platycarpum root exerts immunomodulatory activity via MAPK and NF-κB pathways in RAW264.7 cells. *J Ethnopharmacol* 2021; **281**: 114519 [PMID: 34390795 DOI: 10.1016/j.jep.2021.114519]

96 **Liu JJ**, Xu Y, Chen S, Hao CF, Liang J, Li ZL. The mechanism of Yinchenhao decoction in treating obstructive-jaundice-induced liver injury based on Nrf2 signaling pathway. *World J Gastroenterol* 2022; **28**: 4635-4648 [PMID: 36157920 DOI: 10.3748/wjg.v28.i32.4635]

97 **Wu YL**, Li ZL, Zhang XB, Liu H. Yinchenhao decoction attenuates obstructive jaundice-induced liver injury and hepatocyte apoptosis by suppressing protein kinase RNA-like endoplasmic reticulum kinase-induced pathway. *World J Gastroenterol* 2019; **25**: 6205-6221 [PMID: 31749592 DOI: 10.3748/wjg.v25.i41.6205]

98 **Meng Y**, Meng K, Zhao X, Li D, Gao Q, Wu S, Cui Y. Protective Effects of Yinchenhao Decoction on Cholesterol Gallstone in Mice Fed a Lithogenic Diet by Regulating LXR, CYP7A1, CYP7B1, and HMGCR Pathways. *Evid Based Complement Alternat Med* 2018; **2018**: 8134918 [PMID: 30310412 DOI: 10.1155/2018/8134918]

99 **Mocan T**, Horhat A, Mois E, Graur F, Tefas C, Craciun R, Nenu I, Spârchez M, Sparchez Z. Endoscopic or percutaneous biliary drainage in hilar cholangiocarcinoma: When and how? *World J Gastrointest Oncol* 2021; **13**: 2050-2063 [PMID: 35070041 DOI: 10.4251/wjgo.v13.i12.2050]

100 **Moole H**, Bechtold M, Puli SR. Efficacy of preoperative biliary drainage in malignant obstructive jaundice: a meta-analysis and systematic review. *World J Surg Oncol* 2016; **14**: 182 [PMID: 27400651 DOI: 10.1186/s12957-016-0933-2]

101 **Kwan JR**, Low KSH, Lohan R, Shelat VG. Percutaneous transhepatic biliary drainage catheter fracture: A case report. *Ann Hepatobiliary Pancreat Surg* 2018; **22**: 282-286 [PMID: 30215051 DOI: 10.14701/ahbps.2018.22.3.282]

102 **Xu C**, Lv PH, Huang XE, Sun L, Wang SX, Wang FA. Internal-external percutaneous transhepatic biliary drainage for patients with malignant obstructive jaundice. *Asian Pac J Cancer Prev* 2014; **15**: 9391-9394 [PMID: 25422230 DOI: 10.7314/apjcp.2014.15.21.9391]

103 **Haq TU**, Sanaullah M, Mohsin H, Sheikh MY, Ahmed B. Percutaneous transhepatic biliary stenting. *J Pak Med Assoc* 2001; **51**: 308-312 [PMID: 11715902]

104 **Covey AM**, Brown KT. Percutaneous transhepatic biliary drainage. *Tech Vasc Interv Radiol* 2008; **11**: 14-20 [PMID: 18725138 DOI: 10.1053/j.tvir.2008.05.003]

105 **Sheng Y**, Fu X, Wang G, Mu M, Jiang W, Chen Z, Qi H, Gao F. Safety and efficacy of self-expandable metallic stent combined with (125)I brachytherapy for the treatment of malignant obstructive jaundice. *Cancer Imaging* 2023; **23**: 33 [PMID: 37016400 DOI: 10.1186/s40644-023-00551-0]

106 **Pang Q**, Zhou L, Hu XS, Wang Y, Man ZR, Yang S, Wang W, Qian Z, Jin H, Liu HC. Biliary stenting alone versus biliary stenting combined with (125)I particles intracavitary irradiation for the treatment of advanced cholangiocarcinoma. *Sci Rep* 2019; **9**: 11348 [PMID: 31383886 DOI: 10.1038/s41598-019-47791-4]

107 **Handke NA**, Ollig A, Attenberger UI, Luetkens JA, Faron A, Pieper CC, Schmeel FC, Kupczyk PA, Meyer C, Kuetting D. Percutaneous transhepatic biliary drainage: a retrospective single-center study of 372 patients. *Acta Radiol* 2023; **64**: 1322-1330 [PMID: 36128748 DOI: 10.1177/02841851221127809]

108 **Rees J**, Mytton J, Evison F, Mangat KS, Patel P, Trudgill N. The outcomes of biliary drainage by percutaneous transhepatic cholangiography for the palliation of malignant biliary obstruction in England between 2001 and 2014: a retrospective cohort study. *BMJ Open* 2020; **10**: e033576 [PMID: 31980509 DOI: 10.1136/bmjopen-2019-033576]

109 **Arakura N**, Takayama M, Ozaki Y, Maruyama M, Chou Y, Kodama R, Ochi Y, Hamano H, Nakata T, Kajikawa S, Tanaka E, Kawa S. Efficacy of preoperative endoscopic nasobiliary drainage for hilar cholangiocarcinoma. *J Hepatobiliary Pancreat Surg* 2009; **16**: 473-477 [PMID: 19300895 DOI: 10.1007/s00534-009-0076-8]

110 **Zhang RL**, Cheng L, Cai XB, Zhao H, Zhu F, Wan XJ. Comparison of the safety and effectiveness of endoscopic biliary decompression by nasobiliary catheter and plastic stent placement in acute obstructive cholangitis. *Swiss Med Wkly* 2013; **143**: w13823 [PMID: 23832310 DOI: 10.4414/smw.2013.13823]

111 **Mi N**, Zhang S, Zhu Z, Yu Y, Li W, Zheng L, Chu L, Li J. Randomized Controlled Trial of Modified Nasobiliary Fixation and Drainage Technique. *Front Surg* 2022; **9**: 791945 [PMID: 35284479 DOI: 10.3389/fsurg.2022.791945]

112 **Hu B**, Sun B, Cai Q, Wong Lau JY, Ma S, Itoi T, Moon JH, Yasuda I, Zhang X, Wang HP, Ryozawa S, Rerknimitr R, Li W, Kutsumi H, Lakhtakia S, Shiomi H, Ji M, Li X, Qian D, Yang Z, Zheng X. Asia-Pacific consensus guidelines for endoscopic management of benign biliary strictures. *Gastrointest Endosc* 2017; **86**: 44-58 [PMID: 28283322 DOI: 10.1016/j.gie.2017.02.031]

113 **Nakai Y**, Isayama H, Wang HP, Rerknimitr R, Khor C, Yasuda I, Kogure H, Moon JH, Lau J, Lakhtakia S, Ratanachu-Ek T, Seo DW, Lee DK, Makmun D, Dy F, Liao WC, Draganov PV, Almadi M, Irisawa A, Katanuma A, Kitano M, Ryozawa S, Fujisawa T, Wallace MB, Itoi T, Devereaux B. International consensus statements for endoscopic management of distal biliary stricture. *J Gastroenterol Hepatol* 2020; **35**: 967-979 [PMID: 31802537 DOI: 10.1111/jgh.14955]

114 **Xiang JX**, Maithel SK, Weber SM, Poultsides G, Wolfgang C, Jin L, Fields RC, Weiss M, Scoggins C, Idrees K, Shen P, Zhang XF, Pawlik TM. Impact of Preoperative Jaundice and Biliary Drainage on Short- and Long-term Outcomes among Patients with Gallbladder Cancer. *J Gastrointest Surg* 2023; **27**: 105-113 [PMID: 36376722 DOI: 10.1007/s11605-022-05523-6]

115 **Liu F**, Li Y, Wei Y, Li B. Preoperative biliary drainage before resection for hilar cholangiocarcinoma: whether or not? A systematic review. *Dig Dis Sci* 2011; **56**: 663-672 [PMID: 20635143 DOI: 10.1007/s10620-010-1338-7]

116 **Almadi MA**, Barkun A, Martel M. Plastic vs. Self-Expandable Metal Stents for Palliation in Malignant Biliary Obstruction: A Series of Meta-Analyses. *Am J Gastroenterol* 2017; **112**: 260-273 [PMID: 27845340 DOI: 10.1038/ajg.2016.512]

117 **Dumonceau JM**, Tringali A, Papanikolaou IS, Blero D, Mangiavillano B, Schmidt A, Vanbiervliet G, Costamagna G, Devière J, García-Cano J, Gyökeres T, Hassan C, Prat F, Siersema PD, van Hooft JE. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated October 2017. *Endoscopy* 2018; **50**: 910-930 [PMID: 30086596 DOI: 10.1055/a-0659-9864]

118 **Zorrón Pu L**, de Moura EG, Bernardo WM, Baracat FI, Mendonça EQ, Kondo A, Luz GO, Furuya Júnior CK, Artifon EL. Endoscopic stenting for inoperable malignant biliary obstruction: A systematic review and meta-analysis. *World J Gastroenterol* 2015; **21**: 13374-13385 [PMID: 26715823 DOI: 10.3748/wjg.v21.i47.13374]

119 **Sawas T**, Al Halabi S, Parsi MA, Vargo JJ. Self-expandable metal stents versus plastic stents for malignant biliary obstruction: a meta-analysis. *Gastrointest Endosc* 2015; **82**: 256-267.e7 [PMID: 25982849 DOI: 10.1016/j.gie.2015.03.1980]

120 **Mohanka R**, Rao P, Golhar A, Nikam V, Shrimal A, Shah M, Shukla A, Pargewar S, Bhade R, Gadre P, Dholu R. Archimedes Absorbable Internal Biliary Stent in Liver Transplants to Prevent Bile Leak. *Transplant Proc* 2021; **53**: 2923-2928 [PMID: 34756648 DOI: 10.1016/j.transproceed.2021.09.020]

121 **Mazzola M**, Bertoglio CL, Giani A, Zironda A, Carnevali P, Lombardi PM, De Martini P, Magistro C, Ferrari G. Novel biodegradable internal stent as a mitigation strategy in high-risk pancreaticojejunostomy: technical notes and preliminary results. *Surg Today* 2022; **52**: 1115-1119 [PMID: 35301554 DOI: 10.1007/s00595-022-02488-6]

122 **Shah T**. Drug-eluting stents in malignant biliary obstruction: where do we stand? *Dig Dis Sci* 2013; **58**: 610-612 [PMID: 23250674 DOI: 10.1007/s10620-012-2507-7]

123 **Tsuchiya T**, Itoi T, Sofuni A, Tonozuka R, Mukai S. Endoscopic ultrasonography-guided rendezvous technique. *Dig Endosc* 2016; **28** Suppl 1: 96-101 [PMID: 26786389 DOI: 10.1111/den.12611]

124 **Chan KS**, Teo ZHT, Oo AM, Junnarkar SP, Shelat VG. Learning Curve of Laparoscopic Common Bile Duct Exploration: A Systematic Review. *J Laparoendosc Adv Surg Tech A* 2023; **33**: 241-252 [PMID: 36161969 DOI: 10.1089/lap.2022.0382]

125 **Lim SH**, Tan HTA, Shelat VG. Comparison of indocyanine green dye fluorescent cholangiography with intra-operative cholangiography in laparoscopic cholecystectomy: a meta-analysis. *Surg Endosc* 2021; **35**: 1511-1520 [PMID: 33398590 DOI: 10.1007/s00464-020-08164-5]

126 **Tan YP**, Lim C, Junnarkar SP, Huey CWT, Shelat VG. 3D Laparoscopic common bile duct exploration with primary repair by absorbable barbed suture is safe and feasible. *J Clin Transl Res* 2021; **7**: 473-478 [PMID: 34667894]

127 **Lee T**, Teng TZJ, Shelat VG. Choledochoscopy: An update. *World J Gastrointest Endosc* 2021; **13**: 571-592 [PMID: 35070020 DOI: 10.4253/wjge.v13.i12.571]

128 **Croome KP**, Farnell MB, Que FG, Reid-Lombardo KM, Truty MJ, Nagorney DM, Kendrick ML. Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches? *Ann Surg* 2014; **260**: 633-8; discussion 638-40 [PMID: 25203880 DOI: 10.1097/SLA.0000000000000937]

129 **Kantor O**, Talamonti MS, Sharpe S, Lutfi W, Winchester DJ, Roggin KK, Bentrem DJ, Prinz RA, Baker MS. Laparoscopic pancreaticoduodenectomy for adenocarcinoma provides short-term oncologic outcomes and long-term overall survival rates similar to those for open pancreaticoduodenectomy. *Am J Surg* 2017; **213**: 512-515 [PMID: 28049562 DOI: 10.1016/j.amjsurg.2016.10.030]

130 **Gouma DJ**, van Geenen R, van Gulik T, de Wit LT, Obertop H. Surgical palliative treatment in bilio-pancreatic malignancy. *Ann Oncol* 1999; **10** Suppl 4: 269-272 [PMID: 10436838]

**Footnotes**

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** March 20, 2023

**First decision:** April 21, 2023

**Article in press:** May 31, 2023

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C, C, C, C

Grade D (Fair): D, D


Grade E (Poor): 0

**P-Reviewer:** Aoki H, Japan; Khan M, Pakistan; Liu K, China; Shelat VG, Singapore; Tsujinaka S, Japan **S-Editor:** Yan JP **L-Editor:** A **P-Editor:** Yan JP

**Figure Legends**



**Figure 1 Pathophysiological consequences for obstructive jaundice.**



**Figure 2 The treatment for obstructive jaundice.** PTCD: Percutaneous transhepatic cholangiodrainage; PTBS: Percutaneous transhepatic biliary stenting; ENBD: Endoscopic nasociliary drainage; ERBD: Endoscopic retrograde biliary drainage; EUS-BD: Endoscopic ultrasound-guided biliary drainage; LCBDE+LC: Laparoscopic common bile duct exploration with cholecystectomy.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**